1. Public capital de-risks R&D
- Up to $100 million in CHIPS funding can accelerate superconducting R&D without giving government control.
RGT
RGTI
USD 11.21
-67.37% · 1Y
Mixed · debated
Price
Full synthesis
Viewpoint Synthesis
Bull Thesis
RGTI’s public funding and commercial traction can lower execution risk and extend its runway, supporting a long-term quantum-computing upside case.
2. Commercial reach is expanding
- New deals broaden customer reach, while substantial cash relative to quarterly burn supports continued execution.
3. Investor interest is building
- Analyst coverage and sector-wide buying may broaden attention, though neither establishes company-specific execution.
- Quantum-sector rallies suggest appetite for the category can amplify RGTI’s upside when sentiment improves.
Bear Thesis
RGTI’s valuation leaves limited room for execution setbacks, while delayed government funding could pressure sales.
1. Valuation raises downside risk
- After a sharp rally, expectations may already price in substantial long-term success, capping upside and magnifying misses.
2. Funding delays threaten conversion
- Delayed government approvals can push out sales, raising estimates risk despite announced funding opportunities.
Opinion timeline
Opinion Timeline
Bull Plane
TIME
Bear Plane
The company's stock increased in sympathy with a major acquisition in the quantum sector.
2026-10-27
Back to thesis
2026-10-27
No bear argument in this report.
RGTI signed definitive agreements for up to $100M in US CHIPS Act funding to accelerate superconducting quantum computing R&D.
2026-09-08
Back to thesis
2026-09-08
No bear argument in this report.
Benchmark initiated coverage with a Buy rating.
2026-07-27
Back to thesis
Quantum computing stocks, including RGTI, saw a significant bid, which is an interesting indicator given they topped a couple of weeks before general semis.
2026-07-27
Back to thesis
2026-07-27
No bear argument in this report.
The company is making commercial progress with new deals and has solid liquidity.
2025-11-03
Back to thesis
2025-11-03
The stock's valuation is stretched after a massive YTD rally, pricing in much of its long-term potential.
2025-11-03
Back to thesis
Delayed government funding approvals pose a risk to sales.
2025-11-03
Back to thesis
Sources and method
Research through 2026-10-27 · 2025-11-03 to 2026-10-27 · 6 source reports.
| Range | Prices through |
|---|---|
| 1W | |
| 1M | |
| 3M | |
| 6M | |
| 1Y | |
| 2Y | |
| 3Y |